目次

Chapter- 1: Introduction
Study Goals and Objectives
Reasons for Doing This Study
What's New in This Update
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter- 2: Summary and Highlights
Table 0A : Global Market for Cancer Biologics, by Product Type, Through 2026
Figure 0A : Global Market Shares of Cancer Biologics, by Product Type, 2020
Table 0B : Global Market for Cancer Biologics, by Region, Through 2026
Figure 0B : Global Market Shares of Cancer Biologics, by Region, 2020

Chapter- 3: Clinical Overview
Definition of Cancer
Risk Factors for and Causes of Cancer
Overview of Common Cancer Treatments
Overview of Cancer Burden and Related Costs

Chapter- 4: Cancer Types
Lung Cancer
Bladder Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma
Liver Cancer
Melanoma
Brain Cancer
Ovarian Cancer
Prostate Cancer
Stomach Cancer

Chapter- 5: Cancer Epidemiology
Epidemiology by Cancer Type/Site
Cancer Epidemiology by Region

Chapter- 6: Key Marketed Products
Current Drugs and Recent Approvals
Sales Statistics of Selected Key Biologics

Chapter- 7: Cancer Clinical Trials and Pipeline Biologics
Overview of Cancer Clinical Trials
Key Pipeline Drugs by Company
Key Pipeline Drug Profiles

Chapter- 8: Impact of COVID-19 Pandemic on the Market for Cancer Biologics
Overview
Impact of COVID-19 on Cancer Care

Chapter- 9: Market Breakdown by Product and Technology
Monoclonal Antibodies
CAR T-Cell Therapy
Cancer Vaccines
Table 68 : Global Market for Cancer Biologics, by Product Type, Through 2026
Figure 25 : Global Market Shares of Cancer Biologics, by Product Type, 2020

Chapter- 10: Market Breakdown by Region
Global Market Overview
North America
Europe
Asia-Pacific
Rest of the World

Chapter- 11: Cancer Biologics Market Outlook: Issues and Trends
Medicare Coverage and Reimbursement for Cancer Care
Pricing Strategies for Cancer Biologics
Cancer Drug Costs
Personalized Medicine
Overview of Biosimilars
Biosimilars and Costs of Cancer Drugs
Biosimilars in India and China
Hurdles For Biosimilars
Biosimilars in Europe
Data Exclusivity Periods
Differences Between Biopharmaceuticals and Biogenerics
Biosimilars and Patient Safety

Chapter- 12: Competitive Landscape
Competitive Overview
Competitive Share Analysis
Key Merger and Acquisitions in the Global Cancer Market
Key Licensing Deals in Global Cancer Market

Chapter- 13: Company Profiles
AMGEN INC.
ASTRAZENECA
BRISTOL MYERS SQUIBB
ELI LILLY AND CO.
GENMAB
GILEAD SCIENCES INC.
GLAXOSMITHKLINE
JANSSEN PHARMACEUTICALS INC.
MERCK & CO.
NOVARTIS
PFIZER INC.
ROCHE (F. HOFFMANN-LA ROCHE AG)

Chapter- 14: Appendix: Acronyms
Table 107 : Acronyms Used in This Report